<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00723398</url>
  </required_header>
  <id_info>
    <org_study_id>26970</org_study_id>
    <nct_id>NCT00723398</nct_id>
  </id_info>
  <brief_title>Nutritional Supplements and Hormonal Manipulations for Breast Cancer Prevention</brief_title>
  <official_title>Combination of Low Dose Antiestrogens With Omega-3 Fatty Acids for Prevention of Hormone-independent Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall hypothesis is that the combination of a low dose of the antiestrogen Raloxifene
      with omega-3 fatty acids will exert a synergistic breast cancer chemopreventive effect due to
      the crosstalk of their downstream cellular effects leading to decreased proliferation and
      increased apoptosis of premalignant mammary cells. Based on the investigators hypothesis that
      upregulation of functional estrogen receptors in the premalignant lesions is also responsible
      for the development of hormone independent tumors, the investigators postulate that the
      combination of antiestrogens and omega-3 fatty acids will reduce the development of both
      hormone-dependent and -independent tumors. At present, there are no known interventions able
      to decrease the development of hormone-independent tumors, which are more prevalent, more
      aggressive, leading to the patient's demise. In addition, the investigators postulate that
      this approach will be safe since it will combine a lower and hence a less toxic dose of
      Raloxifene with the administration of omega-3 fatty acids which are known to have health
      benefits, i.e., reduction in cardiovascular risk, beyond their possible chemo preventive
      effect in breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objectives of this study are to determine the individual and combined effects of
      Raloxifene and omega-3 fatty acids on surrogate markers of breast cancer development in
      healthy, postmenopausal women. The primary endpoint will be mammographic density for which
      the study has been powered. Breast density is a major risk factor for breast cancer and hence
      it is chosen to evaluate the potential chemopreventive efficacy of our interventions.
      Secondary endpoints would include markers of oxidative stress, parameters of estrogen
      metabolism, markers of inflammation, and markers of IGF-I signaling, all of which have been
      shown in the literature to have an influence on mammary carcinogenesis.

      Study Population: Healthy, postmenopausal women between the ages of 35-70 years, undergoing
      yearly mammograms as part of routine screening practice.

      Method of Identification of Subjects/Samples/Medical Records: Women reporting for yearly
      mammograms will be considered for this protocol. They will be given first a screening
      questionnaire to rule out any co-existing medical condition that would predispose them to
      thromboembolic events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Absolute Breast Density</measure>
    <time_frame>2 years</time_frame>
    <description>Change of absolute breast density as indicated by mammography from baseline to Year +1 and completion of study (Year +2). No other mammograms will be obtained or used for the purpose of this study. Absolute breast density volume is based on breast thickness and the x-ray attenuation at each pixel of the image.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Biomarkers for Oxidative Stress:Urinary 8-(Isoprostane) F-2α</measure>
    <time_frame>1 year</time_frame>
    <description>Changes in biomarkers for oxidative stress. Specific time points for evaluation are baseline and Year +1 (only). Urinary 8-(isoprostane) F-2α as measured through urine analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Biomarkers for Oxidative Stress: Urinary 8-hydroxy-deoxyguansine</measure>
    <time_frame>1 year</time_frame>
    <description>Changes in biomarkers for oxidative stress. Specific time points for evaluation are baseline and Year +1 (only). Urinary 8-hydroxy-deoxyguansine as measured through urinary analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Biomarkers for Estrogen Metabolism: 2-hydroxy Estrone (Urinary 2-OHE1) and 16-α-hydroxy Estrone (16α-OHE1)</measure>
    <time_frame>1 year</time_frame>
    <description>Changes in biomarkers for estrogen metabolism: 2-hydroxy estrone (Urinary 2-OHE1) and 16-α-hydroxy estrone (16α-OHE1) as measured by urinary analysis. Specific time points for evaluation are baseline and Year +1 (only).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Serum Biomarkers for Inflammation From Levels of High Sensitivity C-reactive Protein (hsCRP) and Interleukin 6 (IL-6)</measure>
    <time_frame>1 Year</time_frame>
    <description>Changes in serum biomarkers for inflammation including highly sensitive C-reactive protein and IL-6 obtained through a blood draw. Specific time points for evaluation are baseline and Year +1 (only).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Insulin-like Growth Factor-1 (IGF-1) and Insulin-like Growth Factor-1 Binding Protein-3 (IGFBP-3)</measure>
    <time_frame>1 year</time_frame>
    <description>Changes in insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-1 binding protein-3 (IGFBP-3) obtained through blood sample. Specific time points for evaluation are baseline and Year +1 (only).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Serum Lipid Levels</measure>
    <time_frame>2 years</time_frame>
    <description>Changes in serum lipid levels as measured through total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides. Specific time points for evaluation are baseline, Year +1, and Year 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Complete Blood Count: Red Blood Cells</measure>
    <time_frame>2 years</time_frame>
    <description>Changes in complete blood count levels as measured through red blood cells (RBC). Specific time points for evaluation are baseline, Year +1, and Year 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Complete Blood Count: Hemoglobin</measure>
    <time_frame>2 years</time_frame>
    <description>Changes in complete blood count levels as measured through hemoglobin. Specific time points for evaluation are baseline, Year +1, and Year 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Complete Blood Count: Hematocrit</measure>
    <time_frame>2 years</time_frame>
    <description>Changes in complete blood count levels as measured through hematocrit percentage. Specific time points for evaluation are baseline, Year +1, and Year 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Complete Blood Count: White Blood Cells and Platelets</measure>
    <time_frame>2 years</time_frame>
    <description>Changes in complete blood count levels as measured through white blood cells (WBC) and platelets. Specific time points for evaluation are baseline, Year +1, and Year 2.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">266</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Group 1: Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control, no intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Raloxifene 60 Mg Oral Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Raloxifene 60 mg Orally Daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Raloxifene 30 Mg Oral Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Raloxifene 30 mg Orally Daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: Lovaza 4 gm oral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lovaza 4 gm/day Orally with Meals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5: Lovaza 4gm &amp; Raloxifene 30mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lovaza 4 gm/day oral capsule with meals plus Raloxifene 30 mg oral tablet daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lovaza 4gm oral</intervention_name>
    <description>Dietary supplement; Take 4 mg oral capsules daily</description>
    <arm_group_label>Group 4: Lovaza 4 gm oral</arm_group_label>
    <other_name>Omega-3 Fatty Acid Capsules; Fish Oil capsules; Triklo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raloxifene 60 Mg Oral Tablet</intervention_name>
    <description>60 mg orally every day for two years</description>
    <arm_group_label>Group 2: Raloxifene 60 Mg Oral Tablet</arm_group_label>
    <other_name>Evista 60 Mg Oral Tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raloxifene 30 Mg Oral Tablet</intervention_name>
    <description>30 mg orally daily for two years</description>
    <arm_group_label>Group 3: Raloxifene 30 Mg Oral Tablet</arm_group_label>
    <other_name>Evista 30 Mg Oral Tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lovaza 4gm &amp; Raloxifene 30mg</intervention_name>
    <description>Lovaza 4gm and Raloxifene 30 Mg orally once per day for 2 years</description>
    <arm_group_label>Group 5: Lovaza 4gm &amp; Raloxifene 30mg</arm_group_label>
    <other_name>Pitavastatin 4 gm and Evista 30 mg oral tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal status defined as history of at least 12 months without spontaneous
             menstrual bleeding or a documented hysterectomy and bilateral salpingo oophorectomy

          -  Breast density greater than 25%

          -  No hormone replacement therapy for at least six months prior to entry into this study

          -  Non-smokers.

        Exclusion Criteria:

          -  History of stroke, pulmonary embolism or deep vein thrombosis

          -  History of atherosclerotic heart disease

          -  Presence of any known hypercoagulable state either congenital (e.g., protein S
             deficiency) or acquired (e.g., corticosteroid treatment)

          -  Diabetes mellitus

          -  Uncontrolled hypertension (BP ≥140/90)

          -  Presence of a psychiatric condition that would interfere with adherence to the
             protocol.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Manni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn State Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>July 24, 2008</study_first_submitted>
  <study_first_submitted_qc>July 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2008</study_first_posted>
  <results_first_submitted>September 6, 2018</results_first_submitted>
  <results_first_submitted_qc>October 1, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 1, 2018</results_first_posted>
  <last_update_submitted>October 1, 2018</last_update_submitted>
  <last_update_submitted_qc>October 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Andrea Manni</investigator_full_name>
    <investigator_title>Professor and Chief Division of Endocrinology, Diabetes, and Metabolism</investigator_title>
  </responsible_party>
  <keyword>omega-3 fatty acids</keyword>
  <keyword>antiestrogens</keyword>
  <keyword>breast cancer prevention</keyword>
  <keyword>breast density</keyword>
  <keyword>biomarkers of mammary carcinogenesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raloxifene Hydrochloride</mesh_term>
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1: Control</title>
          <description>Control, no intervention</description>
        </group>
        <group group_id="P2">
          <title>Group 2: Raloxifene 60 mg</title>
          <description>Raloxifene 60 mg Orally Daily</description>
        </group>
        <group group_id="P3">
          <title>Group 3: Raloxifene 30 mg</title>
          <description>Raloxifene 30 mg Orally Daily</description>
        </group>
        <group group_id="P4">
          <title>Group 4: Lovaza 4 gm</title>
          <description>Lovaza 4 gm/day Orally with Meals</description>
        </group>
        <group group_id="P5">
          <title>Group 5: Lovaza 4 gm and Raloxifene 30 mg</title>
          <description>Lovaza 4 gm/day orally with meals plus Raloxifene 30 mg orally daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="53"/>
                <participants group_id="P4" count="54"/>
                <participants group_id="P5" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="49"/>
                <participants group_id="P5" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1: Control</title>
          <description>Control, no intervention</description>
        </group>
        <group group_id="B2">
          <title>Group 2: Raloxifene 60 mg</title>
          <description>Raloxifene 60 mg Orally Daily</description>
        </group>
        <group group_id="B3">
          <title>Group 3: Raloxifene 30 mg</title>
          <description>Raloxifene 30 mg Orally Daily</description>
        </group>
        <group group_id="B4">
          <title>Group 4: Lovaza 4 gm</title>
          <description>Lovaza 4 gm/day Orally with Meals</description>
        </group>
        <group group_id="B5">
          <title>Group 5: Lovaza 4 gm and Raloxifene 30 mg</title>
          <description>Lovaza 4 gm/day orally with meals plus Raloxifene 30 mg orally daily</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
            <count group_id="B2" value="53"/>
            <count group_id="B3" value="53"/>
            <count group_id="B4" value="54"/>
            <count group_id="B5" value="53"/>
            <count group_id="B6" value="266"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="46"/>
                    <measurement group_id="B6" value="231"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="54"/>
                    <measurement group_id="B5" value="53"/>
                    <measurement group_id="B6" value="266"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="53"/>
                    <measurement group_id="B6" value="264"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="53"/>
                    <measurement group_id="B6" value="259"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Absolute Breast Density</title>
        <description>Change of absolute breast density as indicated by mammography from baseline to Year +1 and completion of study (Year +2). No other mammograms will be obtained or used for the purpose of this study. Absolute breast density volume is based on breast thickness and the x-ray attenuation at each pixel of the image.</description>
        <time_frame>2 years</time_frame>
        <population>The decrease in the population groups is accounted for through subject withdrawals, subjects lost to follow-up, and other reasons for not completing study.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Control</title>
            <description>Control, no intervention</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Raloxifene 60 mg</title>
            <description>Raloxifene 60 mg Orally Daily</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Raloxifene 30 mg</title>
            <description>Raloxifene 30 mg Orally Daily</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Lovaza 4 gm</title>
            <description>Lovaza 4 gm/day Orally with Meals</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Lovaza 4 gm and Raloxifene 30 mg</title>
            <description>Lovaza 4 gm/day orally with meals plus Raloxifene 30 mg orally daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Absolute Breast Density</title>
          <description>Change of absolute breast density as indicated by mammography from baseline to Year +1 and completion of study (Year +2). No other mammograms will be obtained or used for the purpose of this study. Absolute breast density volume is based on breast thickness and the x-ray attenuation at each pixel of the image.</description>
          <population>The decrease in the population groups is accounted for through subject withdrawals, subjects lost to follow-up, and other reasons for not completing study.</population>
          <units>cm squared</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Absolute density at baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="53"/>
                    <count group_id="O4" value="54"/>
                    <count group_id="O5" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.53" spread="59.43"/>
                    <measurement group_id="O2" value="64.39" spread="39.95"/>
                    <measurement group_id="O3" value="65.08" spread="34.47"/>
                    <measurement group_id="O4" value="56.35" spread="22.61"/>
                    <measurement group_id="O5" value="63.81" spread="29.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute density at 1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="50"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.29" spread="40.72"/>
                    <measurement group_id="O2" value="60.48" spread="38.89"/>
                    <measurement group_id="O3" value="59.53" spread="30.32"/>
                    <measurement group_id="O4" value="58.87" spread="22.21"/>
                    <measurement group_id="O5" value="60.93" spread="24.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute density at 2 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="48"/>
                    <count group_id="O5" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.34" spread="20.11"/>
                    <measurement group_id="O2" value="60.57" spread="35.10"/>
                    <measurement group_id="O3" value="58.86" spread="27.93"/>
                    <measurement group_id="O4" value="57.60" spread="20.77"/>
                    <measurement group_id="O5" value="28.53" spread="25.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Biomarkers for Oxidative Stress:Urinary 8-(Isoprostane) F-2α</title>
        <description>Changes in biomarkers for oxidative stress. Specific time points for evaluation are baseline and Year +1 (only). Urinary 8-(isoprostane) F-2α as measured through urine analysis.</description>
        <time_frame>1 year</time_frame>
        <population>Biomarker measurements were not taken for the entire population of the study due to non-significant trends for treatment effects found in this population (n = 47).</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Control</title>
            <description>Control, no intervention</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Raloxifene 60 mg</title>
            <description>Raloxifene 60 mg Orally Daily</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Raloxifene 30 mg</title>
            <description>Raloxifene 30 mg Orally Daily</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Lovaza 4 gm</title>
            <description>Lovaza 4 gm/day Orally with Meals</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Lovaza 4 gm and Raloxifene 30 mg</title>
            <description>Lovaza 4 gm/day orally with meals plus Raloxifene 30 mg orally daily</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Biomarkers for Oxidative Stress:Urinary 8-(Isoprostane) F-2α</title>
          <description>Changes in biomarkers for oxidative stress. Specific time points for evaluation are baseline and Year +1 (only). Urinary 8-(isoprostane) F-2α as measured through urine analysis.</description>
          <population>Biomarker measurements were not taken for the entire population of the study due to non-significant trends for treatment effects found in this population (n = 47).</population>
          <units>pg/mg creatinine</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="544" spread="105"/>
                    <measurement group_id="O2" value="366" spread="39.7"/>
                    <measurement group_id="O3" value="530" spread="107"/>
                    <measurement group_id="O4" value="440" spread="30.8"/>
                    <measurement group_id="O5" value="444" spread="54.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="484" spread="77.3"/>
                    <measurement group_id="O2" value="360" spread="33.8"/>
                    <measurement group_id="O3" value="538" spread="67.0"/>
                    <measurement group_id="O4" value="313" spread="45.1"/>
                    <measurement group_id="O5" value="396" spread="40.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Biomarkers for Oxidative Stress: Urinary 8-hydroxy-deoxyguansine</title>
        <description>Changes in biomarkers for oxidative stress. Specific time points for evaluation are baseline and Year +1 (only). Urinary 8-hydroxy-deoxyguansine as measured through urinary analysis.</description>
        <time_frame>1 year</time_frame>
        <population>Biomarker measurements were not taken for the entire population of the study due to non-significant trends for treatment effects found in this population (n = 47).</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Control</title>
            <description>Control, no intervention</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Raloxifene 60 mg</title>
            <description>Raloxifene 60 mg Orally Daily</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Raloxifene 30 mg</title>
            <description>Raloxifene 30 mg Orally Daily</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Lovaza 4 gm</title>
            <description>Lovaza 4 gm/day Orally with Meals</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Lovaza 4 gm and Raloxifene 30 mg</title>
            <description>Lovaza 4 gm/day orally with meals plus Raloxifene 30 mg orally daily</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Biomarkers for Oxidative Stress: Urinary 8-hydroxy-deoxyguansine</title>
          <description>Changes in biomarkers for oxidative stress. Specific time points for evaluation are baseline and Year +1 (only). Urinary 8-hydroxy-deoxyguansine as measured through urinary analysis.</description>
          <population>Biomarker measurements were not taken for the entire population of the study due to non-significant trends for treatment effects found in this population (n = 47).</population>
          <units>ng/mg creatinine</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="255" spread="63.6"/>
                    <measurement group_id="O2" value="285" spread="47.7"/>
                    <measurement group_id="O3" value="213" spread="91.0"/>
                    <measurement group_id="O4" value="184" spread="25.6"/>
                    <measurement group_id="O5" value="355" spread="79.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="224" spread="31.8"/>
                    <measurement group_id="O2" value="309" spread="69.0"/>
                    <measurement group_id="O3" value="246" spread="108"/>
                    <measurement group_id="O4" value="177" spread="17.3"/>
                    <measurement group_id="O5" value="297" spread="90.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Biomarkers for Estrogen Metabolism: 2-hydroxy Estrone (Urinary 2-OHE1) and 16-α-hydroxy Estrone (16α-OHE1)</title>
        <description>Changes in biomarkers for estrogen metabolism: 2-hydroxy estrone (Urinary 2-OHE1) and 16-α-hydroxy estrone (16α-OHE1) as measured by urinary analysis. Specific time points for evaluation are baseline and Year +1 (only).</description>
        <time_frame>1 year</time_frame>
        <population>Biomarker measurements were not taken for the entire population of the study due to non-significant trends for treatment effects found in this population (n = 47).</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Control</title>
            <description>Control, no intervention</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Raloxifene 60 mg</title>
            <description>Raloxifene 60 mg Orally Daily</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Raloxifene 30 mg</title>
            <description>Raloxifene 30 mg Orally Daily</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Lovaza 4 gm</title>
            <description>Lovaza 4 gm/day Orally with Meals</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Lovaza 4 gm and Raloxifene 30 mg</title>
            <description>Lovaza 4 gm/day orally with meals plus Raloxifene 30 mg orally daily</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Biomarkers for Estrogen Metabolism: 2-hydroxy Estrone (Urinary 2-OHE1) and 16-α-hydroxy Estrone (16α-OHE1)</title>
          <description>Changes in biomarkers for estrogen metabolism: 2-hydroxy estrone (Urinary 2-OHE1) and 16-α-hydroxy estrone (16α-OHE1) as measured by urinary analysis. Specific time points for evaluation are baseline and Year +1 (only).</description>
          <population>Biomarker measurements were not taken for the entire population of the study due to non-significant trends for treatment effects found in this population (n = 47).</population>
          <units>ng/mg creatinine</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Urinary 2-OHE1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.57" spread="2.3"/>
                    <measurement group_id="O2" value="8.58" spread="1.0"/>
                    <measurement group_id="O3" value="8.82" spread="1.4"/>
                    <measurement group_id="O4" value="7.15" spread="1.1"/>
                    <measurement group_id="O5" value="15.6" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year: Urinary 2-OHE1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.46" spread="1.4"/>
                    <measurement group_id="O2" value="10.03" spread="1.0"/>
                    <measurement group_id="O3" value="9.10" spread="1.4"/>
                    <measurement group_id="O4" value="7.49" spread="1.0"/>
                    <measurement group_id="O5" value="13.2" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: 16α-OHE1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.22" spread="0.7"/>
                    <measurement group_id="O2" value="5.08" spread="0.5"/>
                    <measurement group_id="O3" value="6.86" spread="1.8"/>
                    <measurement group_id="O4" value="5.24" spread="0.5"/>
                    <measurement group_id="O5" value="6.6" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year: 16α-OHE1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.68" spread="0.7"/>
                    <measurement group_id="O2" value="4.35" spread="0.5"/>
                    <measurement group_id="O3" value="7.46" spread="1.4"/>
                    <measurement group_id="O4" value="4.79" spread="0.3"/>
                    <measurement group_id="O5" value="5.68" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Serum Biomarkers for Inflammation From Levels of High Sensitivity C-reactive Protein (hsCRP) and Interleukin 6 (IL-6)</title>
        <description>Changes in serum biomarkers for inflammation including highly sensitive C-reactive protein and IL-6 obtained through a blood draw. Specific time points for evaluation are baseline and Year +1 (only).</description>
        <time_frame>1 Year</time_frame>
        <population>Biomarker measurements were not taken for the entire population of the study (N = 266) due to non-significant trends for treatment effects found in this initial population (n = 89).</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Control</title>
            <description>Control, no intervention</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Raloxifene 60 mg</title>
            <description>Raloxifene 60 mg Orally Daily</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Raloxifene 30 mg</title>
            <description>Raloxifene 30 mg Orally Daily</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Lovaza 4 gm</title>
            <description>Lovaza 4 gm/day Orally with Meals</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Lovaza 4 gm and Raloxifene 30 mg</title>
            <description>Lovaza 4 gm/day orally with meals plus Raloxifene 30 mg orally daily</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Serum Biomarkers for Inflammation From Levels of High Sensitivity C-reactive Protein (hsCRP) and Interleukin 6 (IL-6)</title>
          <description>Changes in serum biomarkers for inflammation including highly sensitive C-reactive protein and IL-6 obtained through a blood draw. Specific time points for evaluation are baseline and Year +1 (only).</description>
          <population>Biomarker measurements were not taken for the entire population of the study (N = 266) due to non-significant trends for treatment effects found in this initial population (n = 89).</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Serum hsCRP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.39" spread="0.87"/>
                    <measurement group_id="O2" value="0.91" spread="0.26"/>
                    <measurement group_id="O3" value="1.67" spread="0.63"/>
                    <measurement group_id="O4" value="1.22" spread="0.31"/>
                    <measurement group_id="O5" value="4.28" spread="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year: Serum hsCRP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.19" spread="0.63"/>
                    <measurement group_id="O2" value="1.04" spread="0.34"/>
                    <measurement group_id="O3" value="1.34" spread="0.34"/>
                    <measurement group_id="O4" value="1.69" spread="0.59"/>
                    <measurement group_id="O5" value="2.59" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Serum IL-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" spread="0.3"/>
                    <measurement group_id="O2" value="1.14" spread="0.23"/>
                    <measurement group_id="O3" value="1.04" spread="0.22"/>
                    <measurement group_id="O4" value="1.32" spread="0.45"/>
                    <measurement group_id="O5" value="1.84" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year: Serum IL-6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" spread="0.19"/>
                    <measurement group_id="O2" value="1.13" spread="0.26"/>
                    <measurement group_id="O3" value="1.11" spread="0.2"/>
                    <measurement group_id="O4" value="1.49" spread="0.41"/>
                    <measurement group_id="O5" value="1.32" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Insulin-like Growth Factor-1 (IGF-1) and Insulin-like Growth Factor-1 Binding Protein-3 (IGFBP-3)</title>
        <description>Changes in insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-1 binding protein-3 (IGFBP-3) obtained through blood sample. Specific time points for evaluation are baseline and Year +1 (only).</description>
        <time_frame>1 year</time_frame>
        <population>Measurements were not taken for the entire population of the study due to non-significant trends for treatment effects found in this population (n = 46).</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Control</title>
            <description>Control, no intervention</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Raloxifene 60 mg</title>
            <description>Raloxifene 60 mg Orally Daily</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Raloxifene 30 mg</title>
            <description>Raloxifene 30 mg Orally Daily</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Lovaza 4 gm</title>
            <description>Lovaza 4 gm/day Orally with Meals</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Lovaza 4 gm and Raloxifene 30 mg</title>
            <description>Lovaza 4 gm/day orally with meals plus Raloxifene 30 mg orally daily</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Insulin-like Growth Factor-1 (IGF-1) and Insulin-like Growth Factor-1 Binding Protein-3 (IGFBP-3)</title>
          <description>Changes in insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-1 binding protein-3 (IGFBP-3) obtained through blood sample. Specific time points for evaluation are baseline and Year +1 (only).</description>
          <population>Measurements were not taken for the entire population of the study due to non-significant trends for treatment effects found in this population (n = 46).</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: IGF-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.96" spread="0.37"/>
                    <measurement group_id="O2" value="4.63" spread="0.28"/>
                    <measurement group_id="O3" value="4.80" spread="0.23"/>
                    <measurement group_id="O4" value="4.95" spread="0.41"/>
                    <measurement group_id="O5" value="4.89" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year: IGF-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.05" spread="0.44"/>
                    <measurement group_id="O2" value="4.40" spread="0.25"/>
                    <measurement group_id="O3" value="4.76" spread="0.24"/>
                    <measurement group_id="O4" value="4.96" spread="031"/>
                    <measurement group_id="O5" value="4.82" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: IGFBP-3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.67" spread="0.32"/>
                    <measurement group_id="O2" value="7.53" spread="0.19"/>
                    <measurement group_id="O3" value="7.69" spread="0.21"/>
                    <measurement group_id="O4" value="7.83" spread="0.20"/>
                    <measurement group_id="O5" value="7.57" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year: IGFBP-3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.75" spread="0.26"/>
                    <measurement group_id="O2" value="7.55" spread="0.12"/>
                    <measurement group_id="O3" value="7.79" spread="0.24"/>
                    <measurement group_id="O4" value="7.83" spread="0.17"/>
                    <measurement group_id="O5" value="7.61" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Serum Lipid Levels</title>
        <description>Changes in serum lipid levels as measured through total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides. Specific time points for evaluation are baseline, Year +1, and Year 2.</description>
        <time_frame>2 years</time_frame>
        <population>The decrease in the population groups is accounted for through subject withdrawals, subjects lost to follow-up, and other reasons for not completing study.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Control</title>
            <description>Control, no intervention</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Raloxifene 60 mg</title>
            <description>Raloxifene 60 mg Orally Daily</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Raloxifene 30 mg</title>
            <description>Raloxifene 30 mg Orally Daily</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Lovaza 4 gm</title>
            <description>Lovaza 4 gm/day Orally with Meals</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Lovaza 4 gm and Raloxifene 30 mg</title>
            <description>Lovaza 4 gm/day orally with meals plus Raloxifene 30 mg orally daily</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Serum Lipid Levels</title>
          <description>Changes in serum lipid levels as measured through total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides. Specific time points for evaluation are baseline, Year +1, and Year 2.</description>
          <population>The decrease in the population groups is accounted for through subject withdrawals, subjects lost to follow-up, and other reasons for not completing study.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Total Cholesterol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="54"/>
                    <count group_id="O5" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207.3" spread="41.18"/>
                    <measurement group_id="O2" value="203.6" spread="29.98"/>
                    <measurement group_id="O3" value="204.3" spread="36.29"/>
                    <measurement group_id="O4" value="197.7" spread="33.2"/>
                    <measurement group_id="O5" value="197.6" spread="38.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year: Total Cholestrol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208.8" spread="34.39"/>
                    <measurement group_id="O2" value="198.3" spread="29.33"/>
                    <measurement group_id="O3" value="199.6" spread="28.43"/>
                    <measurement group_id="O4" value="199.6" spread="30.45"/>
                    <measurement group_id="O5" value="189.4" spread="33.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 year: Total Cholesterol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="49"/>
                    <count group_id="O5" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207.5" spread="36.41"/>
                    <measurement group_id="O2" value="196.6" spread="30.64"/>
                    <measurement group_id="O3" value="202.3" spread="25.58"/>
                    <measurement group_id="O4" value="200.2" spread="34.55"/>
                    <measurement group_id="O5" value="192.6" spread="30.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: LDL Cholesterol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="54"/>
                    <count group_id="O5" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114" spread="38.07"/>
                    <measurement group_id="O2" value="114.7" spread="27.53"/>
                    <measurement group_id="O3" value="111.2" spread="31.83"/>
                    <measurement group_id="O4" value="106.6" spread="31.96"/>
                    <measurement group_id="O5" value="108.1" spread="35.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year: LDL Cholesterol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.1" spread="31.99"/>
                    <measurement group_id="O2" value="106.8" spread="25.98"/>
                    <measurement group_id="O3" value="106.2" spread="24.38"/>
                    <measurement group_id="O4" value="109.7" spread="29.22"/>
                    <measurement group_id="O5" value="96.58" spread="26.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 year: LDL Cholesterol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="49"/>
                    <count group_id="O5" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.3" spread="29.21"/>
                    <measurement group_id="O2" value="104.7" spread="28.13"/>
                    <measurement group_id="O3" value="106.1" spread="25.4"/>
                    <measurement group_id="O4" value="110.4" spread="29.2"/>
                    <measurement group_id="O5" value="99.48" spread="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: HDL Cholesterol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="54"/>
                    <count group_id="O5" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.75" spread="18.83"/>
                    <measurement group_id="O2" value="66.18" spread="15.47"/>
                    <measurement group_id="O3" value="70.92" spread="18.54"/>
                    <measurement group_id="O4" value="68.06" spread="16.89"/>
                    <measurement group_id="O5" value="68.9" spread="17.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year: HDL Cholesterol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.71" spread="18.87"/>
                    <measurement group_id="O2" value="68.88" spread="14.06"/>
                    <measurement group_id="O3" value="70.59" spread="16.63"/>
                    <measurement group_id="O4" value="70.59" spread="18.31"/>
                    <measurement group_id="O5" value="76.11" spread="18.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 year: HDL Cholestrol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="49"/>
                    <count group_id="O5" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.19" spread="19.35"/>
                    <measurement group_id="O2" value="68.63" spread="15.04"/>
                    <measurement group_id="O3" value="73.17" spread="18.01"/>
                    <measurement group_id="O4" value="70.67" spread="19.38"/>
                    <measurement group_id="O5" value="75.77" spread="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Triglycerides</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="54"/>
                    <count group_id="O5" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.7" spread="54.57"/>
                    <measurement group_id="O2" value="113.2" spread="48.39"/>
                    <measurement group_id="O3" value="110.6" spread="50.49"/>
                    <measurement group_id="O4" value="115.1" spread="52.33"/>
                    <measurement group_id="O5" value="103.6" spread="38.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year: Triglycerides</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.5" spread="62.95"/>
                    <measurement group_id="O2" value="113.2" spread="55.08"/>
                    <measurement group_id="O3" value="113.7" spread="49.76"/>
                    <measurement group_id="O4" value="96.22" spread="42.94"/>
                    <measurement group_id="O5" value="83.71" spread="31.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 year: Triglycerides</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="49"/>
                    <count group_id="O5" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.1" spread="44.25"/>
                    <measurement group_id="O2" value="116.9" spread="50.17"/>
                    <measurement group_id="O3" value="115.8" spread="58.48"/>
                    <measurement group_id="O4" value="95.41" spread="49.6"/>
                    <measurement group_id="O5" value="86.43" spread="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Complete Blood Count: Red Blood Cells</title>
        <description>Changes in complete blood count levels as measured through red blood cells (RBC). Specific time points for evaluation are baseline, Year +1, and Year 2.</description>
        <time_frame>2 years</time_frame>
        <population>The decrease in the population groups is accounted for through subject withdrawals, subjects lost to follow-up, and other reasons for not completing study.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Control</title>
            <description>Control, no intervention</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Raloxifene 60 mg</title>
            <description>Raloxifene 60 mg Orally Daily</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Raloxifene 30 mg</title>
            <description>Raloxifene 30 mg Orally Daily</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Lovaza 4 gm</title>
            <description>Lovaza 4 gm/day Orally with Meals</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Lovaza 4 gm and Raloxifene 30 mg</title>
            <description>Lovaza 4 gm/day orally with meals plus Raloxifene 30 mg orally daily</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Complete Blood Count: Red Blood Cells</title>
          <description>Changes in complete blood count levels as measured through red blood cells (RBC). Specific time points for evaluation are baseline, Year +1, and Year 2.</description>
          <population>The decrease in the population groups is accounted for through subject withdrawals, subjects lost to follow-up, and other reasons for not completing study.</population>
          <units>millions of cells per microliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: RBC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="50"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.31" spread="0.33"/>
                    <measurement group_id="O2" value="4.25" spread="0.30"/>
                    <measurement group_id="O3" value="4.30" spread="0.33"/>
                    <measurement group_id="O4" value="4.33" spread="0.43"/>
                    <measurement group_id="O5" value="4.24" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year: RBC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="50"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.27" spread="0.32"/>
                    <measurement group_id="O2" value="4.19" spread="0.25"/>
                    <measurement group_id="O3" value="4.25" spread="0.30"/>
                    <measurement group_id="O4" value="4.36" spread="0.44"/>
                    <measurement group_id="O5" value="4.20" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 year: RBC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="49"/>
                    <count group_id="O5" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.32" spread="0.36"/>
                    <measurement group_id="O2" value="4.20" spread="0.23"/>
                    <measurement group_id="O3" value="4.24" spread="0.35"/>
                    <measurement group_id="O4" value="4.33" spread="0.45"/>
                    <measurement group_id="O5" value="4.23" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Complete Blood Count: Hemoglobin</title>
        <description>Changes in complete blood count levels as measured through hemoglobin. Specific time points for evaluation are baseline, Year +1, and Year 2.</description>
        <time_frame>2 years</time_frame>
        <population>The decrease in the population groups is accounted for through subject withdrawals, subjects lost to follow-up, and other reasons for not completing study.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Control</title>
            <description>Control, no intervention</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Raloxifene 60 mg</title>
            <description>Raloxifene 60 mg Orally Daily</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Raloxifene 30 mg</title>
            <description>Raloxifene 30 mg Orally Daily</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Lovaza 4 gm</title>
            <description>Lovaza 4 gm/day Orally with Meals</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Lovaza 4 gm and Raloxifene 30 mg</title>
            <description>Lovaza 4 gm/day orally with meals plus Raloxifene 30 mg orally daily</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Complete Blood Count: Hemoglobin</title>
          <description>Changes in complete blood count levels as measured through hemoglobin. Specific time points for evaluation are baseline, Year +1, and Year 2.</description>
          <population>The decrease in the population groups is accounted for through subject withdrawals, subjects lost to follow-up, and other reasons for not completing study.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Hemoglobin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="50"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.09" spread="1.56"/>
                    <measurement group_id="O2" value="13.11" spread="1.48"/>
                    <measurement group_id="O3" value="12.73" spread="2.02"/>
                    <measurement group_id="O4" value="13.25" spread="0.99"/>
                    <measurement group_id="O5" value="13.35" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year: Hemoglobin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="50"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.97" spread="1.49"/>
                    <measurement group_id="O2" value="12.97" spread="1.61"/>
                    <measurement group_id="O3" value="12.95" spread="0.96"/>
                    <measurement group_id="O4" value="13.33" spread="0.97"/>
                    <measurement group_id="O5" value="13.10" spread="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 year: Hemoglobin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="49"/>
                    <count group_id="O5" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.10" spread="0.87"/>
                    <measurement group_id="O2" value="13.07" spread="0.71"/>
                    <measurement group_id="O3" value="12.82" spread="0.96"/>
                    <measurement group_id="O4" value="13.16" spread="0.91"/>
                    <measurement group_id="O5" value="13.22" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Complete Blood Count: Hematocrit</title>
        <description>Changes in complete blood count levels as measured through hematocrit percentage. Specific time points for evaluation are baseline, Year +1, and Year 2.</description>
        <time_frame>2 years</time_frame>
        <population>The decrease in the population groups is accounted for through subject withdrawals, subjects lost to follow-up, and other reasons for not completing study.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Control</title>
            <description>Control, no intervention</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Raloxifene 60 mg</title>
            <description>Raloxifene 60 mg Orally Daily</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Raloxifene 30 mg</title>
            <description>Raloxifene 30 mg Orally Daily</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Lovaza 4 gm</title>
            <description>Lovaza 4 gm/day Orally with Meals</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Lovaza 4 gm and Raloxifene 30 mg</title>
            <description>Lovaza 4 gm/day orally with meals plus Raloxifene 30 mg orally daily</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Complete Blood Count: Hematocrit</title>
          <description>Changes in complete blood count levels as measured through hematocrit percentage. Specific time points for evaluation are baseline, Year +1, and Year 2.</description>
          <population>The decrease in the population groups is accounted for through subject withdrawals, subjects lost to follow-up, and other reasons for not completing study.</population>
          <units>volume percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Hematocrit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="50"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.14" spread="2.50"/>
                    <measurement group_id="O2" value="38.95" spread="2.49"/>
                    <measurement group_id="O3" value="38.79" spread="3.06"/>
                    <measurement group_id="O4" value="39.09" spread="2.70"/>
                    <measurement group_id="O5" value="39.20" spread="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year: Hematocrit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="50"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.83" spread="2.25"/>
                    <measurement group_id="O2" value="38.79" spread="2.14"/>
                    <measurement group_id="O3" value="38.43" spread="2.69"/>
                    <measurement group_id="O4" value="39.52" spread="2.72"/>
                    <measurement group_id="O5" value="39.14" spread="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 year: Hematocrit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="49"/>
                    <count group_id="O5" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.00" spread="2.47"/>
                    <measurement group_id="O2" value="38.86" spread="2.28"/>
                    <measurement group_id="O3" value="38.31" spread="2.84"/>
                    <measurement group_id="O4" value="38.59" spread="5.72"/>
                    <measurement group_id="O5" value="39.14" spread="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Complete Blood Count: White Blood Cells and Platelets</title>
        <description>Changes in complete blood count levels as measured through white blood cells (WBC) and platelets. Specific time points for evaluation are baseline, Year +1, and Year 2.</description>
        <time_frame>2 years</time_frame>
        <population>The decrease in the population groups is accounted for through subject withdrawals, subjects lost to follow-up, and other reasons for not completing study.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Control</title>
            <description>Control, no intervention</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Raloxifene 60 mg</title>
            <description>Raloxifene 60 mg Orally Daily</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Raloxifene 30 mg</title>
            <description>Raloxifene 30 mg Orally Daily</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Lovaza 4 gm</title>
            <description>Lovaza 4 gm/day Orally with Meals</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Lovaza 4 gm and Raloxifene 30 mg</title>
            <description>Lovaza 4 gm/day orally with meals plus Raloxifene 30 mg orally daily</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Complete Blood Count: White Blood Cells and Platelets</title>
          <description>Changes in complete blood count levels as measured through white blood cells (WBC) and platelets. Specific time points for evaluation are baseline, Year +1, and Year 2.</description>
          <population>The decrease in the population groups is accounted for through subject withdrawals, subjects lost to follow-up, and other reasons for not completing study.</population>
          <units>thousand cells/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: WBC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="50"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.13" spread="1.29"/>
                    <measurement group_id="O2" value="5.47" spread="1.57"/>
                    <measurement group_id="O3" value="5.00" spread="1.20"/>
                    <measurement group_id="O4" value="5.04" spread="1.64"/>
                    <measurement group_id="O5" value="5.27" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year: WBC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="50"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.15" spread="1.76"/>
                    <measurement group_id="O2" value="5.51" spread="1.54"/>
                    <measurement group_id="O3" value="4.78" spread="1.04"/>
                    <measurement group_id="O4" value="4.95" spread="1.37"/>
                    <measurement group_id="O5" value="4.91" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 year: WBC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="49"/>
                    <count group_id="O5" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.14" spread="1.32"/>
                    <measurement group_id="O2" value="5.42" spread="1.39"/>
                    <measurement group_id="O3" value="4.90" spread="1.10"/>
                    <measurement group_id="O4" value="4.90" spread="1.26"/>
                    <measurement group_id="O5" value="4.91" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Platelets</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="50"/>
                    <count group_id="O4" value="51"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270.70" spread="277.46"/>
                    <measurement group_id="O2" value="235.22" spread="52.06"/>
                    <measurement group_id="O3" value="240.42" spread="41.32"/>
                    <measurement group_id="O4" value="237.33" spread="51.41"/>
                    <measurement group_id="O5" value="235.76" spread="53.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year: Platelets</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="41"/>
                    <count group_id="O4" value="50"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="237.02" spread="55.05"/>
                    <measurement group_id="O2" value="228.02" spread="50.71"/>
                    <measurement group_id="O3" value="230.61" spread="39.40"/>
                    <measurement group_id="O4" value="231.42" spread="49.58"/>
                    <measurement group_id="O5" value="221.49" spread="55.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 year: Platelets</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="49"/>
                    <count group_id="O5" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="234.02" spread="47.55"/>
                    <measurement group_id="O2" value="226.16" spread="51.14"/>
                    <measurement group_id="O3" value="232.09" spread="44.10"/>
                    <measurement group_id="O4" value="232.47" spread="54.22"/>
                    <measurement group_id="O5" value="223.27" spread="49.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants who did not meet an off study criterion were followed until 2 years post initiation of the study medication regimen.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1: Control</title>
          <description>Control, no intervention</description>
        </group>
        <group group_id="E2">
          <title>Group 2: Raloxifene 60 mg</title>
          <description>Raloxifene 60 mg Orally Daily</description>
        </group>
        <group group_id="E3">
          <title>Group 3: Raloxifene 30 mg</title>
          <description>Raloxifene 30 mg Orally Daily</description>
        </group>
        <group group_id="E4">
          <title>Group 4: Lovaza 4 gm</title>
          <description>Lovaza 4 gm/day Orally with Meals</description>
        </group>
        <group group_id="E5">
          <title>Group 5: Lovaza 4 gm and Raloxifene 30 mg</title>
          <description>Lovaza 4 gm/day orally with meals plus Raloxifene 30 mg orally daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI CTC V 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometrial Cancer</sub_title>
                <description>Endometrial Cancer (unlikely a secondary malignancy- likely new primary)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>NCI CTC V 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="53"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Night Sweating (diaphoresis)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Leg cramping</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal Spotting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rosacea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Andrea Manni</name_or_title>
      <organization>Milton S. Hershey Medical Center</organization>
      <phone>717-531-8395</phone>
      <email>amanni@pennstatehealth.psu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

